Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Recruiting · NCT06974617 · Interventional (participants receive a specific treatment) · Lead sponsor: Cairo University
View the official record on ClinicalTrials.gov →Interventions studied
Botulinum Toxin Type ASphenopalatine block
What this trial is about
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 18 and 65 years.
- Both sexes.
- Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.
Exclusion criteria
- Patients with medication over use headache.
- Bleeding disorders.
- Abnormal neurological examination.
- History of allergy to local anesthetics or BOTOX.
Where it is running
1 location listed.
- Cairo University - Cairo, Egypt